Content
Cannabis Growth Q4 Financials Unimpressive
Article By:
Lorimer Wilson
Read
Friday, May 31, 2024 4:00 PM EDT
The CEO and CFO believe that Canopy's portfolio of high-impact brands, a rapidly developing U.S. ecosystem and no material debt maturing until 2026 make Canopy well equipped to capitalize on growth opportunities and enhance shareholder value.
In this article: CGC
All 12 Constituents In The Cannabis Portfolios Declined W/e May 24th
Article By:
Lorimer Wilson
Read
Monday, May 27, 2024 4:00 PM EDT
All 12 constituents declined w/e by an average of 14.4% and are now down 28.9%, on average, since Tuesday, April 30th, when the DEA announced it planned to reclassify cannabis as a less regulated drug.
Regular Cannabis Users Exceeds Drinkers For First Time Ever
Article By:
Tyler Durden
Read
Monday, May 27, 2024 12:00 AM EDT
For the first time, a nationwide study on tobacco, alcohol, drug use, mental health, and other health issues found that daily cannabis use has surpassed daily beer or vodka consumption.
European Cannabis Q1 2024 Quarterly Update
Article By:
Michael Sassano
Read
Tuesday, May 21, 2024 3:00 PM EDT
2024 ushered in one of the most reformatory changes that the global medical cannabis community has ever witnessed.
American Cannabis MSOs Portfolio Reversed Direction Last Week
Article By:
Lorimer Wilson
Read
Sunday, May 19, 2024 4:45 PM EDT
This article highlights how each constituent in the Portfolio fared last week and MTD along with their reported Q1 profit or loss and their Q1 adjusted EBITDA as a percentage of quarterly revenue for comparison purposes:
AYR Wellness' Q1 Financials Reveal 94% Reduction In Net Loss
Article By:
Lorimer Wilson
Read
Wednesday, May 15, 2024 5:06 PM EDT
First quarter results reflect continued progress with modest sequential revenue growth, adjusted EBITDA margins in line with long-term targets of 25% and positive free cash flow for the period.
In this article: AYRWF
All Cresco Labs' QI Financial Metrics Down Except SG&A
Article By:
Lorimer Wilson
Read
Wednesday, May 15, 2024 12:51 PM EDT
Despite the poor Q1 financial report Cresco's stock price is UP 2.5% as of mid-day but is still DOWN 1.9% from last Friday albeit UP 52.6% YTD.
In this article: CRLBF
Organigram Q2 Financial Metrics Mixed
Article By:
Lorimer Wilson
Read
Tuesday, May 14, 2024 2:00 PM EDT
Of the top 3 licensed producers in Canada Organigram is the only one with significant cash, negligible debt, and sizeable funds earmarked for strategic international investment.
In this article: OGI
Cronos Q1 Financial Metrics Show Improvement; Stock Climbs 3%
Article By:
Lorimer Wilson
Read
Sunday, May 12, 2024 6:39 PM EDT
Cronos Group's stock price was up 25.4% in Q1 (January, February, March), rose 8.8% between then and the release of the Q1 report on May 9th, before slipping by 2.8% the following day. The stock is now up 32.5% YTD.
In this article: CRON